The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma

Kai Ozaki | Shingo Hatakeyama | Toshikazu Tanaka | Daisuke Noro | Noriko Tokui | Hirotaka Horiguchi | Yoshiharu Okuyama | Naoki Fujita | Teppei Okamoto | Akiko Okamoto | Yuichiro Suzuki | Hayato Yamamoto | Takahiro Yoneyama | Yasuhiro Hashimoto | Chikara Ohyama

1Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
2Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan
3Department of Urology, Mutsu General Hospital, Mutsu, Japan
4Department of Urology, Odate Municipal Hospital, Odate, Japan
5Department of Urology, Oyokyo Kidney Research Institute, Hirosaki, Japan
6Department of Urology, Aomori City Hospital, Aomori, Japan
7Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

Correspondence
Shingo Hatakeyama, MD, Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki 036-8562, Japan.
Email: shingoh@hirosaki-u.ac.jp

Funding information
Japan Society for the Promotion of Science, Grant/Award Numbers: 18K16718, 19H05556, 19K18575, 19K18603, 20K09517, 21K16749

Abstract
Objective: To investigate the eligibility for maintenance immunotherapy and its impact on the prognosis of advanced urothelial carcinoma treated with first-line chemotherapy, as the selection biases of the eligible population in the JAVELIN Bladder 100 trial remain unclear.

Methods: We retrospectively evaluated 213 patients (median age, 71 years) with unresectable locally advanced or metastatic urothelial carcinoma treated with platinum-based first-line chemotherapy between May 2003 and April 2021. The patients were categorized into the following two groups: progressive disease (PD) within four cycles (trial ineligible group) and non-PD within four cycles (trial eligible group). The primary outcomes were the estimated proportion of trial eligible patients for maintenance immunotherapy. The secondary outcomes were the comparison of the overall survival in the trial eligible and ineligible groups and the impact of radiologic response at the second cycle on the fourth cycle.

Results: Among the 213 patients, 81 (38%) were included in the trial eligible group. The trial eligible group had a significantly longer overall survival than the trial ineligible group (P < 0.001). Of 166 patients who had no PD within two cycles, 85 (51%) patients experienced PD within four cycles. Patients with a complete response or partial response at the second cycle had a significantly lower rate of PD at the fourth cycle (42%) than those with stable disease at the second cycle (59%, P = 0.031).

Conclusion: We observed 38% of the trial eligible population. Overall survival was significantly different between the trial eligible and ineligible groups.

Keywords
chemotherapy, maintenance immunotherapy, prognosis, radiological response, urothelial carcinoma

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Advanced urothelial carcinoma (UC) is a life-threatening disease with a high mortality rate.\textsuperscript{1,2} Although platinum-based chemotherapy is the standard-of-care and first-line treatment for UC, the prognosis for those patients remains poor because of chemotherapy resistance and accumulating toxicities.\textsuperscript{3-7} The JAVELIN Bladder 100 trial demonstrated that avelumab maintenance therapy is beneficial in patients with unresectable locally advanced or metastatic UC.\textsuperscript{8} However, this study included patients who did not present with disease progression while receiving first-line chemotherapy (four to six cycles of gemcitabine along with cisplatin or carboplatin). To appropriately use avelumab maintenance therapy, it is imperative to identify the selection biases of the eligible population in the JAVELIN Bladder 100 trial to translate the outcomes from clinical trial to clinical practice. Therefore, we aimed to retrospectively investigate the eligibility for maintenance immunotherapy and its impact on prognosis in unresectable locally advanced or metastatic UC in real-world practice. The goal of this study is to identify selection biases of the eligible population in the JAVELIN Bladder 100 trial.

2 | METHODS

2.1 | Design and ethics statement

This retrospective, multicenter study conformed to the principles of Declaration of Helsinki and was approved by the ethics committee of the Hirosaki University School of Medicine (2019–099) and all participating hospitals. Written consent was not obtained unless patients decide to be excluded (opt-out approach).

2.2 | Patient selection

We evaluated 218 patients with unresectable or metastatic UC (T4, N positive, or M1) who received systemic, platinum-based, first-line chemotherapy between May 2003 and April 2021 at one academic center and five general hospitals. We excluded five patients whose tumor response could not be evaluated (n = 2), who were unfit for platinum-based regimens because of severe renal impairment (n = 2) or chronic pulmonary disease (n = 1). In total, we enrolled 213 patients in this study. From the patient records, the following variables were collected and analyzed: age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), renal function (estimated glomerular filtration rate: eGFR), clinical stage, urinary bladder or upper urinary tract UC (UTUC), and metastatic sites. Tumor stage and grade were stratified according to TNM classification (8th edition).\textsuperscript{9} The baseline radiological response was evaluated by RECIST version 1.1 and classified into the following four categories: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Since the trial ineligible patients were not defined and considered in the trial, we defined the trial ineligible group (PD within four cycles) and trial eligible group (non-PD within four cycles).

2.3 | Cisplatin ineligibility

We used the modified cisplatin ineligibility criteria, considering the population difference.\textsuperscript{10} Cisplatin ineligibility was considered if at least one of the following criteria was met: ECOG PS > 1, creatinine clearance < 60 ml/min or eGFR < 50 ml/min/1.73 m², neuropathy grade > 1, hearing loss grade > 1, and/or New York Heart Association Class III heart failure. Cisplatin ineligibility was also defined based on the following marginal criteria: ECOG PS of 1, eGFR of 50–60 ml/min/1.73 m², NYHA Class II heart failure, and age >80 years. Patients with two or more marginal factors, such as ECOG PS 1 and >80 years, were considered cisplatin-ineligible.

2.4 | Platinum-based chemotherapy

Chemotherapy regimens were selected according to our cisplatin eligibility guideline. Patients received one of the following drug combinations: gemcitabine plus cisplatin (GCis), gemcitabine plus carboplatin (GCarbo), GCarbo plus docetaxel (GCarboD), or MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin).\textsuperscript{4,13-15} Drug administration cycle was repeated every 28 days until disease progression or intolerable adverse events occurred. All patients were scanned by computed tomography every two cycles. If PD or intolerable adverse events occurred, the first-line treatment regimen was discontinued and switched to second-line treatment regimen.\textsuperscript{16} Given that the standard second-line regimen was not yet defined before 2018 (pre-pembrolizumab era), some patients were continuously treated with the first-line therapy beyond PD. Our regimens for salvage chemotherapy included docetaxel-based regimes (e.g., docetaxel + ifosfamide + nedaplatin or paclitaxel + gemcitabine),\textsuperscript{17,18} or rechallenge of first-line therapy.

2.5 | Outcomes

The primary outcome was estimating the proportion of the trial eligible patients for maintenance immunotherapy. The secondary outcome included the comparison of the overall survival (OS) between the trial eligible and ineligible groups and the impact of radiologic response at second cycle on fourth cycle. An OS event was defined as the length of time after primary treatment to last follow-up or any cause of death.

2.6 | Statistical analyses

Statistical data were analyzed using BellCurve for Excel 3.2.1 (SSRI Co., Ltd., Tokyo, Japan), GraphPad Prism 7.00 (GraphPad Software, San Diego, CA, U.S.A.), and R version 4.0.2 (The R Foundation, Vienna, Austria). The difference was tested by Student’s t-test, Mann-
Whitney U test, Fisher’s exact test, or χ² test. Means with standard deviations or medians with interquartile ranges (IQRs) was used to express quantitative variables. The OS rate was estimated by log-rank test. The effect of trial eligibility on the OS was investigated by multivariate Cox regression analyses using the inverse probability of treatment weighting (IPTW) model. We also calculated the hazard ratio (HR) with 95% confidence interval (95% CI) after controlling the potential confounders, including patient age, sex, performance status, tumor type, TNM stage, chemotherapy types (cisplatin-based regimen or not), subsequent use of pembrolizumab, and liver metastasis.

3 | RESULTS

3.1 | Baseline characteristics

The median age was 71 years (IQR: 63–78 years). Of the 213 patients, 102 (48%) had UTUC, 153 (72%) received carboplatin-based regimens, and 70 (30%) had unresectable locally advanced (T4 or N+) disease. The median number of cycles of platinum-based chemotherapy was 4 (IQR: 2–4) (Table 1).

3.2 | Primary outcomes

Of 213, 132 (62%) patients had PD within four cycles of first-line chemotherapy (trial ineligible group), suggesting that 81 (38%) patients had no PD within four cycles (trial eligible group, Figure 1A). Of 213, 47 (22%) patients had PD within two cycles of first-line chemotherapy. Of 166 patients who had no PD within two cycles, 85 (51%) patients had PD within four cycles of first-line chemotherapy. The change in the tumor response from second cycle to fourth cycle in CR, PR, SD, and PD were 0.5% to 0.5%, 36% to 25%, 41% to 13%, and 22% to 62%, respectively (Figure 1B). Intergroup patient baseline characteristics were significantly different in terms of the ECOG PS, metastatic disease, and number of patients with first-line chemotherapy of four cycles or more (Table 1).

### TABLE 1  Background of patients

|                | All       | Trial eligible group | Trial ineligible group | P value |
|----------------|-----------|----------------------|------------------------|---------|
| n              | 213       | 81                   | 132                    |         |
| Age, years (IQR) | 71 (63–78) | 72 (63–78)          | 70 (62–77)             | 0.551   |
| Male, n        | 154 (72%) | 60 (74%)             | 94 (70%)               | 0.632   |
| UTUC, n        | 102 (48%) | 41 (51%)             | 61 (46%)               | 0.532   |
| ECOG PS > 1    | 20 (9%)   | 3 (4%)               | 17 (13%)               | 0.026   |
| Disease status, n |          |                      |                        |         |
| unresectable locally advanced (T4 or N+) | 70 (30%) | 40 (49%)             | 30 (23%)               | <0.001  |
| metastatic (M1) | 143 (70%) | 41 (51%)             | 102 (77%)              |         |
| liver metastasis | 15 (7%)  | 3 (4%)               | 12 (9%)                | 0.136   |
| eGFR, ml/min/1.73 m² (IQR) | 57 (45–70) | 57 (43–69)          | 57 (46–71)             | 0.541   |
| Local therapy (surgery or radiotherapy), n | 34 (16%) | 16 (20%)             | 18 (14%)               | 0.377   |
| First-line regimens |          |                      |                        |         |
| cisplatin-based | 60 (28%)  | 21 (25%)             | 39 (30%)               | 0.418   |
| carboplatin-based | 153 (72%) | 60 (74%)             | 93 (70%)               |         |
| Number of cycles of 1st-line therapy (IQR) | 4 (2–4)  | 4 (4–6)              | 3 (2–4)                | <0.001  |
| 4 cycles or more, n | 143 (67%) | 81 (100%)            | 62 (47%)               |         |
| Subsequent pembrolizumab therapy, n | 60 (28%)  | 27 (33%)             | 33 (25%)               | 0.189   |
| Median follow up, months (IQR) | 14 (7–24) | 17 (12–30)          | 10 (6–20)              |         |

Note: IQR: interquartile range, UTUC: upper urinary tract urothelial carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status, and eGFR: estimated glomerular filtration rate.
In the trial eligible group, the CR/PR at second cycle was significantly associated with a lower PD rate at fourth cycle compared with SD at second cycle (42% vs. 59%, \(P = 0.031\), Figure 2D). The subgroup analysis of OS in the trial ineligible group (SD at second cycles to PD at fourth cycles vs. PD within second cycles) was shown in Figure S1. The OS comparison between the trial eligible and ineligible groups in the follow-up duration (<14 or ≥14 months) of treatment periods (before or after 2018) was shown in Figure S2. A visual abstract was in the supplement Figure S3.
4 | DISCUSSION

In this study, we investigated the proportion of the trial eligible population for maintenance immunotherapy and the impact of trial eligibility on the prognosis of patients with unresectable or metastatic UC. Given that the JAVELIN Bladder 100 trial formed an eligible population, we need to recognize the selection biases of this population to translate the outcomes from clinical trial to practice. In our practice, less than half (38%) of patients were eligible for avelumab maintenance therapy, suggesting that more than half of patients were candidates for second-line pembrolizumab therapy. Furthermore, the OS was significantly different between the trial eligible and ineligible groups based on the inclusion criteria. We need to know that avelumab maintenance therapy is effective in selected patients with favorable disease control. Therefore, we could not compare the outcomes of switch maintenance therapy with the other first- or second-line trials in one table. In this regard, our study can provide useful information for proper understanding of treatment, although our study is not useful on deciding to perform immunotherapy or not for each patient. As the goal of this study is to identify selection biases of the eligible population in the JAVELIN Bladder 100 trial, the definition of trial ineligible group and the OS comparison does not necessarily negate the findings of JAVELIN Bladder 100 trial.

Although no study supports the effect of early administration of avelumab maintenance therapy within four cycles of first-line chemotherapy, it might be a potential option considering an immunogenic cell death at the time of best response (i.e., after approximately two or three cycles). In our study, the OS showed marginal difference (P = 0.057) between patients with “PD ≤ 2 cycles or SD (second cycle) to PD (fourth cycle)” and those with “PR (second cycle) to PD (fourth cycle)”.” Patients who had an initial response to first-line chemotherapy might have favorable effects for avelumab maintenance therapy because cytotoxic chemotherapies induce dynamic changes in the tumor immune microenvironment. However, our results showed that the OS was significantly different between the trial eligible and ineligible population, suggesting that disease progression within the first four cycles is a signal of a poor prognosis. Concerning the eligible population formed by the JAVELIN Bladder 100 trial, we need to recognize that level 1 evidence is limited in patients without PD receiving four to six cycles of first-line chemotherapy. Nevertheless, further studies are warranted to determine the optimal timing of maintenance immunotherapy.

Predicting the tumor response on the fourth cycle from the second cycle is important for the indication of avelumab maintenance therapy. Our results showed that patients with CR/PR at two cycles had a significantly higher rate of non-PD on the fourth cycle. Notably, 58% of patients with CR/PR at second cycle maintained CR/PR at fourth cycle (Figure 2E). However, 51% of patients without PD at second cycle experienced PD at fourth cycle. Therefore, the eligibility criteria for the avelumab maintenance therapy are narrow.

In this study, we observed a higher proportion of carboplatin-based regimens (72%). The administration of cisplatin in all patients is not feasible because of renal impairment, older age, poor general status, and/or comorbidities. Nearly 60% of patients with urothelial cancer are reportedly ineligible for cisplatin-based chemotherapies. Although cisplatin ineligibility currently does not have any specific criteria, we used the modified cisplatin ineligibility criteria to secure a safety margin. Considering that our patients were older (median age, 71 years) than those in clinical trials (64–68 years), obtaining a 72% proportion of patients with cisplatin ineligibility is reasonable in a clinical practice.

This study has several limitations that need to be acknowledged. The selection bias and other unmeasurable confounders were not controlled because of the retrospective study design. The statistical analysis may be underpowered because of the small sample size. Also, analyses under a heterogenous population (carboplatin-based regimens and higher UTUC proportion) prevent generalization. Despite the limitations, this study presents the clinical implication of eligibility for maintenance immunotherapy and its impact on prognosis in unresectable or metastatic UC. However, further investigation is necessary to determine the optimal strategies of transition from the first-line platinum-based chemotherapy to maintenance immunotherapy.

4.1 | Conclusion

We observed 38% of eligible patients for avelumab maintenance therapy in our practice. The OS was significantly different between the trial eligible and ineligible groups. CR or PR at two cycles was significantly associated with the eligibility for maintenance immunotherapy.

ACKNOWLEDGMENTS

The authors thank Yuki Fujita for their invaluable support with data collection.

FUNDING INFORMATION

This study was supported by Japan Society for the Promotion of Science (JSPS) Grant Numbers of 19H05556 (C.O.), 20K09517 (S.H.), 19K18603 (N.F.), 19K18575 (Y.S.), 18K16718 (D.N.), and 21K16749 (H.H.).

CONFLICT OF INTEREST

The authors have no conflict of interest.

AUTHORS’ CONTRIBUTIONS

Kai Ozaki: Data collection.
Shingo Hatakeyama: Project development, manuscript editing, data analysis, and data collection, funding acquisition.
Toshikazu Tanaka: Data collection.
Daisuke Noro: Data collection, funding acquisition.
Noriko Tokui: Data collection.
Hirotaka Horiguchi: Data collection, funding acquisition.
Yoshiharu Okuyama: Data collection.
Naoki Fujita: Data collection, funding acquisition.
Teppei Okamoto: Data collection.
Akiko Okamoto: Data collection.
Yuichiro Suzuki: Data collection.
Hayato Yamamoto: Data collection.
Takahiro Yoneyama: Data collection.
Yasuhiro Hashimoto: Data collection.
Chikara Ohyama: Project development and critical review, funding acquisition.

ETHICS STATEMENT
The present retrospective, multicenter study was performed in accordance with the ethical standards of the Declaration of Helsinki, and it was approved by the ethics review board of the Hirosaki University School of Medicine (authorization number: 2019–099) and all hospitals. Pursuant to the provisions of the ethics committee and the ethics guidelines in Japan, written informed consent is not required for public disclosure of study information in the case of a retrospective and/or observational study using materials, such as existing documents (opt-out approach).

REFERENCES
1. VanderWalde NA, Chi MT, Hurria A, Galsky MD, Nielsen ME. Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. World J Urol. 2016;34:3–11.
2. Yuasa T, Urakami S, Yonese J. Recent advances in medical therapy for metastatic urothelial cancer. J Int Clin Oncol. 2018;23:599–607.
3. Matsumoto H, Shiroma K, Azuma H, Inoue K, Uemura H, Eto M, et al. Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: Summary of the revision. Int J Urol. 2020;27:702–9.
4. Wijes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.
5. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.
6. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol. 2012;30:1107–13.
7. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–9.
8. Fukushima K, Narita T, Hatakeyama S, Yamamoto H, Soma O, Matsumoto T, et al. Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. Int J Clin Oncol. 2017;22:366–72.
9. Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, et al. Impact of the number of cycles of platinum based first line chemotherapy for advanced Urothelial carcinoma. J Urol. 2018;200:1207–14.
10. Powles T, Park SH, Voog E, Caserta C, Valderrama B, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic Urothelial carcinoma. N Engl J Med. 2020;383:1218–30.
11. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73:560–9.
12. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432–8.
13. Fliag TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN guidelines insights: Bladder Cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16:1041–53.
14. Yoneyama T, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Hatakeyama S, et al. Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer. Int J Clin Oncol. 2015;20:369–74.
15. Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, et al. The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma. Urol Oncol. 2021.
16. Narita T, Hatakeyama S, Numakura K, Kobayashi M, Muto Y, Saito M, et al. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. Int J Urol. 2021;24:28.
17. Harada M, Tomisaki I, Minato A, Onishi R, Terado M, Inatomi H, et al. Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol. 2021;28:970–4.
18. Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegrisch G, Albers P, et al. Single-agent Taxane versus Taxane-containing combination chemotherapy as salvage therapy for advanced Urothelial carcinoma. Eur Urol. 2016;69:634–41.
19. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79.
20. Kido K, Hatakeyama S, Numakura T, Tanaka T, Oikawa M, Noro D, et al. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: A multicenter retrospective study. Int J Clin Oncol. 2021;26:154–62.
21. Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, et al. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treat Rev. 2021;97:102187.
22. Fucikova J, Kepp O, Kasikova L, Petroni G, Yamanaka T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020 2020/11/26:11:1013.
23. Park YH, Lal S, Lee JE, Choi Y-L, Wen J, Ram S, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020 2020/12/02:11:6175.
24. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet. 2017; 389:67–76.
25. Momota M, Hatakeyama S, Tokui N, Sato T, Yamamoto H, Tobisawa Y, et al. The impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with Urothelial carcinoma. Eur Urol Focus. 2019;5:1066–73.
26. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, et al. Feasibility of Cisplatin-based Neoadjuvant chemotherapy in muscle-invasive bladder Cancer patients with diminished renal function. Clin Genitourin Cancer. 2018;16:e879–92.

27. Galsky MD, Ma E, Shah-Manek B, Mills R, Ha L, Krebsbach C, et al. Cisplatin ineligibility for patients with metastatic Urothelial carcinoma: A survey of clinical practice perspectives among US oncologists. Bladder Cancer. 2019;5:281–8.

28. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211–4.

29. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multi-centre, phase 3 trial. Lancet Oncol. 2020;21:1574–88.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, et al. The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma. BJU Compass. 2022;3(2):139–145. https://doi.org/10.1002/bco2.119